See more : High Peak Royalties Limited (HPR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Acepodia, Inc. (6976.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acepodia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Novozymes A/S (NVZMY) Income Statement Analysis – Financial Results
- Impac Mortgage Holdings, Inc. (IMPHO) Income Statement Analysis – Financial Results
- Kinik Company (1560.TW) Income Statement Analysis – Financial Results
- Jiangsu Maixinlin Aviation Science and Technology Corp. (688685.SS) Income Statement Analysis – Financial Results
- PT Mitra Pemuda Tbk (MTRA.JK) Income Statement Analysis – Financial Results
Acepodia, Inc. (6976.TWO)
About Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its unique antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. The company was founded in 2017 and is headquartered in Grand Cayman, the Cayman Islands.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 16.59M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.59M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 310.94M | 341.59M | 303.45M | 115.53M |
| General & Administrative | 141.63M | 175.97M | 173.84M | 34.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 141.63M | 175.97M | 173.84M | 34.12M |
| Other Expenses | 0.00 | -920.85M | -400.85M | -305.54M |
| Operating Expenses | 452.57M | 517.56M | 477.29M | 149.64M |
| Cost & Expenses | 452.57M | 517.56M | 477.29M | 149.64M |
| Interest Income | 132.24M | 25.55M | 424.00K | 279.00K |
| Interest Expense | 4.84M | 1.51M | 798.00K | 60.00K |
| Depreciation & Amortization | 47.18M | 22.99M | 12.11M | 4.29M |
| EBITDA | -764.52M | -1.39B | -865.61M | -146.75M |
| EBITDA Ratio | -4,607.48% | 0.00% | 0.00% | 0.00% |
| Operating Income | -435.97M | -1.41B | -477.29M | -149.64M |
| Operating Income Ratio | -2,627.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -380.57M | -896.81M | -401.22M | -305.32M |
| Income Before Tax | -816.54M | -1.41B | -878.51M | -454.96M |
| Income Before Tax Ratio | -4,921.01% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 776.00K | 0.00 | -400.43M | -305.26M |
| Net Income | -817.32M | -1.41B | -878.51M | -454.96M |
| Net Income Ratio | -4,925.69% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -30.79 | -77.69 | -40.23 |
| EPS Diluted | -1.44 | -30.79 | -77.69 | -40.23 |
| Weighted Avg Shares Out | 567.02M | 45.94M | 11.31M | 11.31M |
| Weighted Avg Shares Out (Dil) | 567.02M | 45.94M | 11.31M | 11.31M |
Source: https://incomestatements.info
Category: Stock Reports